title: Signal peptide-CUB-EGF domain-containing protein 1 (SCUBE1) level in hemodialysis patients and parameters affecting that level.
abstract: BACKGROUND
  Signal peptide-CUB (complement C1r/C1s, Uegf, and Bmp1)-EGF (epidermal growth factor)-domain-containing protein 1 (SCUBE1) is a cell surface protein belonging to the SCUBE gene family. SCUBE1 has been shown to rise in parallel with platelet activation in acute ischemic events. However, there are no studies showing levels in the hemodialysis patient group, in which there is known to be an increase in platelet function impairment and activation. The purpose of this study was to investigate SCUBE1 levels in a hemodialysis patient group and the factors affecting those levels.
  
  
  METHODS
  One hundred three hemodialysis patients and 21 age-matched healthy controls were included. SCUBE1 and sCD40L levels were investigated from blood specimens collected on pre- and post-hemodialysis sessions. We investigated the correlation between SCUBE1 levels and sCD40L, patients' demographic data, parameters with hemodialysis treatment and routine biochemical tests.
  
  
  RESULTS
  SCUBE1 levels were significantly higher in the hemodialysis patient group compared with the controls (p=0.000). There was a significant rise in SCUBE1 levels in the post-hemodialysis session (p=0.000). We determined a positive correlation between SCUBE1 and sCD40L (p=0.016, r=0.215). Gender, blood pressure, BUN, creatinine, hematocrit and high-sensitivity C-reactive protein (hsCRP) levels, hemodialysis membrane surface area, amount of ultrafiltration, blood flow rate, dialysis flow rate and carnitine use significantly affected SCUBE1 levels.
  
  
  CONCLUSIONS
  We have shown, for the first time in the literature, that SCUBE1 level, a potential acute ischemia marker, is elevated in hemodialysis patients with no clinical ischemic event, and that various factors affect this elevation.
authors.affiliation: Department of Nephrology, Karadeniz Technical University, School of Medicine, Turkey. sulusoy2002@yahoo.com
authors.forename: Sukru
authors.initials: S
authors.lastname: Ulusoy
authors.forename: Gulsum
authors.initials: G
authors.lastname: Ozkan
authors.forename: Ahmet
authors.initials: A
authors.lastname: Menteşe
authors.forename: Adnan
authors.initials: A
authors.lastname: Yavuz
authors.forename: S Caner
authors.initials: SC
authors.lastname: Karahan
authors.forename: Ayşegül Uzun
authors.initials: AU
authors.lastname: Sümer
mesh_terms: D000368:Aged; D023201:CD40 Ligand / Q000097:blood; D002135:Calcium-Binding Proteins; D002331:Carnitine / Q000627:therapeutic use; D016022:Case-Control Studies; D003404:Creatinine / Q000097:blood; D004921:Erythropoietin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D008297:Male; D008565:Membrane Proteins / Q000097:blood*; D008875:Middle Aged; D006435:Renal Dialysis; D014803:Vitamin B Complex / Q000627:therapeutic use
chemical_list: D002135:Calcium-Binding Proteins; D008565:Membrane Proteins; C469998:SCUBE1 protein, human; D004921:Erythropoietin; D014803:Vitamin B Complex; D023201:CD40 Ligand; D003404:Creatinine; D002331:Carnitine